Immunoprecise Antibodies Ltd (IPA) — Capital Reinvestment Ratio
Immunoprecise Antibodies Ltd (IPA) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). See how leveraged is Immunoprecise Antibodies Ltd's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Immunoprecise Antibodies Ltd Capital Reinvestment Ratio (2016–2016)
This chart tracks Immunoprecise Antibodies Ltd's Capital Reinvestment Ratio across 1 annual periods. Check IPA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Immunoprecise Antibodies Ltd (2016–2016)
Year-by-year Capital Reinvestment Ratio for Immunoprecise Antibodies Ltd from 2016 to 2016. For live market cap and broader valuation context, see IPA market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.06x | $284.09K | $17.48K | — |